Cryo-Cell International Overview
Is CCEL undervalued? Intrinsic value estimate stands at $-1.
Get informed when a big investor buys or sells
+ Follow$-1.03
Overvalued by 124.0% based on the discounted cash flow analysis.
As of the most recent data, CCEL shows a DCF fair value of $-1. Scroll down for historical charts and peer comparison views.
Cryo-Cell International's DCF reading of $-1 (124.0% overvalued) is a model output, not a certainty. Small changes in long-term growth or the discount rate can move fair value a lot. Treat the number as a structured starting point, then verify whether Cryo-Cell International's recent cash-flow history supports the assumptions.
Besides this discounted cash flow page, Stockcircle has Cryo-Cell International's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect DCF fair value (currently $-1) with ownership activity and broader fundamentals.
Cryo-Cell International's DCF fair value is $-1; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
